In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction.
Studies were performed to investigate the UDP-glucuronosyltransferase enzyme(s) responsible for the human liver microsomal N2-glucuronidation of the anticonvulsant drug lamotrigine (LTG) and the mechanistic basis for the LTG-valproic acid (VPA) interaction in vivo. LTG N2-glucuronidation by microsomes from five livers exhibited atypical kinetics, best described by a model comprising the expressions for the Hill (1869 +/- 1286 microM, n = 0.65 +/- 0.16) and Michaelis-Menten (Km 2234 +/- 774 microM) equations. The UGT1A4 inhibitor hecogenin abolished the Michaelis-Menten component, without affecting the Hill component. LTG N2-glucuronidation by recombinant UGT1A4 exhibited Michaelis-Menten kinetics, with a Km of 1558 microM. Although recombinant UGT2B7 exhibited only low activity toward LTG, inhibition by zidovudine and fluconazole and activation by bovine serum albumin (BSA) (2%) strongly suggested that this enzyme was responsible for the Hill component of microsomal LTG N2-glucuronidation. VPA (10 mM) abolished the Hill component of microsomal LTG N2-glucuronidation, without affecting the Michaelis-Menten component or UGT1A4-catalyzed LTG metabolism. Ki values for inhibition of the Hill component of LTG N2-glucuronidation by VPA were 2465 +/- 370 microM and 387 +/- 12 microM in the absence and presence, respectively, of BSA (2%). Consistent with published data for the effect of fluconazole on zidovudine glucuronidation by human liver microsomal UGT2B7, the Ki value generated in the presence of BSA predicted the magnitude of the LTG-VPA interaction reported in vivo. These data indicate that UGT2B7 and UGT1A4 are responsible for the Hill and Michaelis-Menten components, respectively, of microsomal LTG N2-glucuronidation, and the LTG-VPA interaction in vivo arises from inhibition of UGT2B7.
Rowland
Andrew
A
Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, SA 5042, Australia.
Elliot
David J
DJ
Williams
J Andrew
JA
Mackenzie
Peter I
PI
Dickinson
Ronald G
RG
Miners
John O
JO
D000927:Anticonvulsants / Q000378:metabolism*; D019540:Area Under Curve; D002460:Cell Line; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015725:Fluconazole / Q000494:pharmacology; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D007700:Kinetics; D000077213:Lamotrigine; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D008954:Models, Biological; D011994:Recombinant Proteins / Q000378:metabolism; D012502:Sapogenins / Q000494:pharmacology; D012710:Serum Albumin, Bovine; D014227:Triazines / Q000378:metabolism*; D014635:Valproic Acid / Q000378:metabolism* / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
D000927:Anticonvulsants; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D011994:Recombinant Proteins; D012502:Sapogenins; D014227:Triazines; C019787:bilirubin glucuronoside glucuronosyltransferase; C074259:lamotrigine 2-N-glucuronide; D012710:Serum Albumin, Bovine; C007908:hecogenin; D015215:Zidovudine; D014635:Valproic Acid; D015725:Fluconazole; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase; D000077213:Lamotrigine